Literature DB >> 18720194

Synthesis, acoustic stability, and pharmacologic activities of papaverine-loaded echogenic liposomes for ultrasound controlled drug delivery.

Patrick H Kee1, Todd A Abruzzo, Denise A B Smith, Jonathan A Kopechek, Boyu Wang, Shaoling L Huang, Robert C MacDonald, Christy K Holland, David D McPherson.   

Abstract

BACKGROUND: development of encapsulated therapeutics that could be released upon ultrasound exposure has strong implications for enhancing drug effects at the target site. We have developed echogenic liposomes (ELIP) suitable for ultrasound imaging of blood flow and ultrasound-mediated intravascular drug release. Papaverine was chosen as the test drug because its clinical application requires high concentration in the target vascular bed but low concentration in the systemic circulation.
METHODS: the procedure for preparation of standard ELIP was modified by including Papaverine hydrochloride in the lipid hydration solution, followed by three freeze-thaw cycles to increase encapsulation of the drug. Sizing and encapsulation pharmacokinetics were performed using a Coulter counter and a phosphodiesterase activity assay. Stability of Papaverine-loaded ELIP (PELIP) was monitored with a clinical diagnostic ultrasound scanner equipped with a linear array transducer at a center frequency of 4.5 MHz by assessing the mean digital intensity within a region of interest over time. The stability of PELIP was compared to those of standard ELIP and Optison.
RESULTS: relative to standard ELIP, PELIP were larger (median diameter = 1.88 +/- 0.10 microm for PELIP vs 1.08 +/- 0.15 microm for ELIP) and had lower Mean Gray Scale Values (MGSV) (92 +/- 24.8 for PELIP compared to 142.3 +/- 10.7 for ELIP at lipid concentrations of 50 microg/ml). The maximum loading efficiency and mean encapsulated concentration were 24% +/- 7% and 2.1 +/- 0.7 mg/ml, respectively. Papaverine retained its phosphodiesterase inhibitory activity when associated with PELIP. Furthermore, a fraction of this activity remained latent until released by dissolution of liposomal membranes with detergent. The stability of both PELIP and standard ELIP were similar, but both are greater than that of Optison.
CONCLUSIONS: our results suggest that PELIP have desirable physical, biochemical, biological, and acoustic characteristics for potential in vivo administration and ultrasound-controlled drug delivery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18720194      PMCID: PMC2846712          DOI: 10.1080/08982100802354558

Source DB:  PubMed          Journal:  J Liposome Res        ISSN: 0898-2104            Impact factor:   3.648


  33 in total

Review 1.  Endovascular treatment of cerebral vasospasm.

Authors:  T P Smith; D S Enterline
Journal:  J Vasc Interv Radiol       Date:  2000-05       Impact factor: 3.464

Review 2.  Endovascular therapy for vasospasm.

Authors:  Jayashree Srinivasan; Joseph Eskridge; M Sean Grady; David W Newell; H Richard Winn
Journal:  Clin Neurosurg       Date:  2002

3.  Effect of intra-arterial papaverine on regional cerebral blood flow in hemodynamically relevant cerebral vasospasm.

Authors:  P Vajkoczy; P Horn; C Bauhuf; E Munch; U Hubner; D Ing; C Thome; C Poeckler-Schoeninger; H Roth; P Schmiedek
Journal:  Stroke       Date:  2001-02       Impact factor: 7.914

4.  Enhancement of ultrasound-accelerated thrombolysis by echo contrast agents: dependence on microbubble structure.

Authors:  K Mizushige; I Kondo; K Ohmori; K Hirao; H Matsuo
Journal:  Ultrasound Med Biol       Date:  1999-11       Impact factor: 2.998

5.  Intraarterial infusion of papaverine and change of cerebral hemodynamics in symptomatic cerebral vasospasm.

Authors:  H Minami; K Kuwamura; N Tamaki
Journal:  Kobe J Med Sci       Date:  2001-08

6.  The efficacy of papaverine administration by different routes for the treatment of experimental acute cerebral vasospasm.

Authors:  Hon-Man Liu; Yong-Kwang Tu
Journal:  J Clin Neurosci       Date:  2002-09       Impact factor: 1.961

7.  Indications for endovascular therapy for refractory vasospasm after aneurysmal subarachnoid hemorrhage: experience at the University of Cincinnati.

Authors:  Norberto Andaluz; Thomas A Tomsick; John M Tew; Harry R van Loveren; Hwa-Shain Yeh; Mario Zuccarello
Journal:  Surg Neurol       Date:  2002-08

8.  Left ventricular thrombus enhancement after intravenous injection of echogenic immunoliposomes: studies in a new experimental model.

Authors:  Andrew Hamilton; Shao-Ling Huang; Drew Warnick; Adam Stein; Mark Rabbat; Taruna Madhav; Bonnie Kane; Ashwin Nagaraj; Melvin Klegerman; Robert MacDonald; David McPherson
Journal:  Circulation       Date:  2002-06-11       Impact factor: 29.690

9.  Ultrasound-mediated release of hydrophilic and lipophilic agents from echogenic liposomes.

Authors:  Jonathan A Kopechek; Todd M Abruzzo; Boyu Wang; Stephen M Chrzanowski; Denise A B Smith; Patrick H Kee; Shaoling Huang; Joel H Collier; David D McPherson; Christy K Holland
Journal:  J Ultrasound Med       Date:  2008-11       Impact factor: 2.153

10.  Multimodal quantitation of the effects of endovascular therapy for vasospasm on cerebral blood flow, transcranial doppler ultrasonographic velocities, and cerebral artery diameters.

Authors:  Rod J Oskouian; Neil A Martin; Jae Hong Lee; Thomas C Glenn; Donald Guthrie; Nestor R Gonzalez; Arash Afari; Fernando Viñuela
Journal:  Neurosurgery       Date:  2002-07       Impact factor: 4.654

View more
  7 in total

Review 1.  In vitro methods to study bubble-cell interactions: Fundamentals and therapeutic applications.

Authors:  Guillaume Lajoinie; Ine De Cock; Constantin C Coussios; Ine Lentacker; Séverine Le Gac; Eleanor Stride; Michel Versluis
Journal:  Biomicrofluidics       Date:  2016-01-28       Impact factor: 2.800

2.  Nitric oxide-loaded echogenic liposomes for nitric oxide delivery and inhibition of intimal hyperplasia.

Authors:  Shao-Ling Huang; Patrick H Kee; Hyunggun Kim; Melanie R Moody; Stephen M Chrzanowski; Robert C Macdonald; David D McPherson
Journal:  J Am Coll Cardiol       Date:  2009-08-11       Impact factor: 24.094

3.  Ultrasound-enhanced delivery of targeted echogenic liposomes in a novel ex vivo mouse aorta model.

Authors:  Kathryn E Hitchcock; Danielle N Caudell; Jonathan T Sutton; Melvin E Klegerman; Deborah Vela; Gail J Pyne-Geithman; Todd Abruzzo; Peppar E P Cyr; Yong-Jian Geng; David D McPherson; Christy K Holland
Journal:  J Control Release       Date:  2010-03-02       Impact factor: 9.776

4.  Ultrasound-triggered release of recombinant tissue-type plasminogen activator from echogenic liposomes.

Authors:  Denise A B Smith; Sampada S Vaidya; Jonathan A Kopechek; Shao-Ling Huang; Melvin E Klegerman; David D McPherson; Christy K Holland
Journal:  Ultrasound Med Biol       Date:  2010-01       Impact factor: 2.998

Review 5.  Ultrasound-mediated drug delivery for cardiovascular disease.

Authors:  Jonathan T Sutton; Kevin J Haworth; Gail Pyne-Geithman; Christy K Holland
Journal:  Expert Opin Drug Deliv       Date:  2013-03-01       Impact factor: 6.648

6.  The impact of bubbles on measurement of drug release from echogenic liposomes.

Authors:  Jonathan A Kopechek; Kevin J Haworth; Kirthi Radhakrishnan; Shao-Ling Huang; Melvin E Klegerman; David D McPherson; Christy K Holland
Journal:  Ultrason Sonochem       Date:  2012-12-29       Impact factor: 7.491

7.  Ultrasound-mediated release of hydrophilic and lipophilic agents from echogenic liposomes.

Authors:  Jonathan A Kopechek; Todd M Abruzzo; Boyu Wang; Stephen M Chrzanowski; Denise A B Smith; Patrick H Kee; Shaoling Huang; Joel H Collier; David D McPherson; Christy K Holland
Journal:  J Ultrasound Med       Date:  2008-11       Impact factor: 2.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.